CRISPR start-ups turn attention toward delivery
CRISPR has had a wild year. The gene-editing tool has been the subject of increasing scrutiny as the first clinical trial using it to treat a genetic disease begins. Scientific controversies about the safety and accuracy of CRISPR gene editing have leapt from the pages of academic journals into the news headlines. And in the biggest bombshell of all, last month a Chinese scientist claimed to create the first two CRISPR-edited embryos born as babies.